Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

NCT00847145 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2249

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL: 1a - rMenB+OMV NZ and routine vaccines
BIOLOGICAL: 1b - rMenB+OMV NZ and routine vaccines
BIOLOGICAL: 2a - Routine and rMenB+OMV NZ vaccines
BIOLOGICAL: 2b - rMenB+OMV NZ and routine vaccines
BIOLOGICAL: 3a - rMenB+OMV NZ and routine vaccines
BIOLOGICAL: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations
BIOLOGICAL: 4a- rMenB+OMV NZ and routine vaccines
BIOLOGICAL: 4b - rMenB+OMV NZ and routine vaccines

Sponsor

Novartis Vaccines